Cellular Effect
| Cell Line | Activity | Value | Description | Reference |
|---|---|---|---|---|
| CCRF-CEM | EC50 | 0.045 μM | Antiviral activity against wild type HIV-1 3B infected in human CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis | [PMID: 23603046] |
| CCRF-CEM | EC50 | 0.062 μM | Antiviral activity against wild type HIV-2 ROD infected in human CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis | [PMID: 23603046] |
| HEK293 | IC50 | 13.5 μM | Inhibition of human OAT1 expressed in HEK293 cells assessed as P-amino hippuric acid uptake inhibition incubated for 10 mins by UPLC-MS/MS method | [PMID: 31301948] |
| HEL | EC50 | 0.2 μM | Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis | [PMID: 23603046] |
| HEL | EC50 | 0.2 μM | Antiviral activity against thymidine kinase-deficient Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis | [PMID: 23603046] |
| HEL | EC50 | 0.2 μM | Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis | [PMID: 23603046] |
| HEL | EC50 | 4 μM | Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis | [PMID: 23603046] |
| HepG2 2.2.15 | CC50 | > 400 μM | Toxicity against human HepG2.2.15 cells infected with HBV after 72 hrs by MTT assay | [PMID: 27458783] |
| HepG2 2.2.15 | IC50 | 0.33 μM | Antiviral activity against Hepatitis B virus infected HepG2(2.2.15) cells assessed as inhibition of viral cytoplasmic DNA synthesis by real-time PCR | [PMID: 19889538] |
| HepG2 2.2.15 | IC50 | 0.48 μM | Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as viral DNA level after 9 days by southern blot analysis | 10.1007/s00044-011-9616-2 |
| HepG2 2.2.15 | IC50 | 0.58 μM | Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 9 days by RT-PCR analysis | 10.1007/s00044-011-9616-2 |
| HepG2 2.2.15 | EC50 | 0.96 μM | Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication incubated for 2 days followed by wash out measured after 10 days by RT-PCR analysis | [PMID: 22305613] |
| HepG2 2.2.15 | EC50 | 1.5 μM | Antiviral activity against wild type HBV infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization | [PMID: 20117930] |
| HepG2 2.2.15 | EC50 | 1.8 μM | Antiviral activity against 3TC-resistant HBV with polymerase M204V mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization | [PMID: 20117930] |
| HepG2 2.2.15 | EC50 | 2 μM | Antiviral activity against 3TC-resistant HBV with polymerase M204I mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization | [PMID: 20117930] |
| HepG2 2.2.15 | EC50 | 2.1 μM | Antiviral activity against 3TC-resistant HBV with polymerase L180M mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization | [PMID: 20117930] |
| HepG2 2.2.15 | EC50 | 2.2 μM | Antiviral activity against 3TC-resistant HBV with polymerase LMMV mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization | [PMID: 20117930] |
| HepG2 2.2.15 | CC50 | 438.92 μM | Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 12 hrs followed by replacement of fresh medium containing compound and measured after 2 days by CCK-8 assay | [PMID: 31301948] |
18 records · Scroll to view more